Devlin R D, Gutteridge D H, Prince R L, Retallack R W, Worth G K
Department of Endocrinology and Diabetes, Sir Charles Gairdner Hospital, Queen Elizabeth II Medical Centre, Nedlands, Western Australia.
J Bone Miner Res. 1990 Nov;5(11):1121-6. doi: 10.1002/jbmr.5650051105.
We report serum 25-hydroxyvitamin D (25-OHD), 24,25-dihydroxyvitamin D [24,25-(OH)2D], and 1,25-dihydroxyvitamin D [1,25-(OH)2D] levels in untreated Paget's disease and the effect of treatment with either calcitonin (CT) or etidronate (EHDP) on these levels. In untreated Paget's patients serum 25-OHD (73 +/- 29 nmol/liter, n = 36, mean +/- SD) and 24,25-(OH)2D (0.3-12.9 nmol/liter, median 2.2, n = 36) levels were significantly lower than in age-matched controls (94 +/- 30 nmol/liter, n = 32, p less than 0.005, and 1.3-16.4 nmol/liter, median 5.3; n = 32, p less than 0.001, respectively). Also, the 24,25-(OH)2D levels correlated with the 25-OHD levels in the untreated Paget's patients (r = 0.56, p less than 0.01) and in the controls (r = 0.39, p less than 0.05). The percentage molar ratio of 24,25-(OH)2D to 25-OHD in Paget's patients had a median value of 3.7% (range 0.4-14.3%), which was not significantly different from controls, who had a median value of 5.6% (range 2.2-18%). There was no difference between the 1,25-(OH)2D, and immunoreactive PTH (iPTH) levels of Paget's patients and control subjects. The percentage molar ratio of 1,25-(OH)2D to 25-OHD in untreated Paget's patients (0.157 +/- 0.09%) was not significantly different from controls (0.124 +/- 0.05%) despite lower 25-OHD levels in Paget's patients. There was a significant inverse correlation between the severity of Paget's disease as measured by plasma alkaline phosphatase (AP) levels and 25-OHD levels (r = 0.392, p less than 0.02); however, 24,25-(OH)2D and 1,25-(OH)2D levels were not correlated with AP.(ABSTRACT TRUNCATED AT 250 WORDS)
我们报告了未经治疗的佩吉特病患者的血清25-羟基维生素D（25-OHD）、24,25-二羟基维生素D[24,25-(OH)₂D]和1,25-二羟基维生素D[1,25-(OH)₂D]水平，以及降钙素（CT）或依替膦酸（EHDP）治疗对这些水平的影响。在未经治疗的佩吉特病患者中，血清25-OHD（73±29nmol/升，n = 36，均值±标准差）和24,25-(OH)₂D（0.3 - 12.9nmol/升，中位数2.2，n = 36）水平显著低于年龄匹配的对照组（94±30nmol/升，n = 32，p＜0.005；以及1.3 - 16.4nmol/升，中位数5.3；n = 32，p＜0.001）。此外，在未经治疗的佩吉特病患者和对照组中，24,25-(OH)₂D水平与25-OHD水平相关（r = 0.56，p＜0.01；r = 0.39，p＜0.05）。佩吉特病患者中24,25-(OH)₂D与25-OHD的摩尔百分比比值中位数为3.7%（范围0.4 - 14.3%），与对照组中位数5.6%（范围2.2 - 18%）无显著差异。佩吉特病患者与对照受试者的1,25-(OH)₂D和免疫反应性甲状旁腺激素（iPTH）水平无差异。尽管佩吉特病患者的25-OHD水平较低，但未经治疗的佩吉特病患者中1,25-(OH)₂D与25-OHD的摩尔百分比比值（0.157±0.09%）与对照组（0.124±0.05%）无显著差异。以血浆碱性磷酸酶（AP）水平衡量的佩吉特病严重程度与25-OHD水平之间存在显著负相关（r = 0.392，p＜0.02）；然而，24,25-(OH)₂D和1,25-(OH)₂D水平与AP无关。（摘要截短至250字）
